I’m sorry, but I don’t have the content of the article to craft a suitable SEO title.

Lead Paragraph The U.S. Food and Drug Administration (FDA) has expanded approval of Moderna’s mRNA-1345 respiratory syncytial virus (RSV) vaccine, branded mRESVIA, to include adults ages 18–59 who have chronic health conditions that heighten their risk of severe RSV disease. The decision, announced 12 June 2025, positions Moderna to compete head-to-head with GSK and Pfizer in a rapidly expanding adult RSV market while underscoring the growing role of mRNA technology beyond COVID-19. Why This Matters • RSV hospitalizes an estimated 177,000 U.S. adults annually and kills about 14,000—figures traditionally associated with seniors but now shown to threaten younger adults living with asthma, diabetes, heart disease or other chronic conditions. • More than one-third of Americans aged 18–59 fall into at-risk categories, giving the new indication significant public-health reach. • The shot is expected to be available this autumn alongside updated COVID-19 boosters and flu vaccines, setting the stage for “tripledemic” prevention strategies during the 2025-2026 respiratory season. How the Vaccine Works mRESVIA delivers a strand of messenger RNA that instructs muscle cells to make a stabilized prefusion F protein found on the RSV virus surface. The immune system then produces neutralizing antibodies against both RSV-A and RSV-B subtypes, providing broad protection. Moderna uses the same lipid-nanoparticle platform that propelled its COVID-19 vaccines to global prominence, streamlining manufacturing and distribution. Clinical-Trial Snapshot • Phase 3 immunobridging study NCT06067230 enrolled adults 18–59 with underlying conditions. • Neutralizing-antibody levels matched or exceeded those seen in adults ≥60 from Moderna’s pivotal efficacy trial. • Common side effects: injection-site pain, fatigue, headache, myalgia and arthralgia—similar to other adult vaccines. • Severe adverse events were rare and comparable to placebo. These data satisfied FDA non-inferiority criteria and paved the way for the label expansion. What It Means for Consumers 1. Eligibility: Adults 18–59 with chronic lung or heart disease, diabetes, weakened immune systems or other physician-identified risk factors. 2. Dosing: A single intramuscular injection; no booster schedule announced yet. 3. Availability: Pharmacies, primary-care offices and community clinics are expected to stock mRESVIA by October 2025, pending CDC Advisory Committee on Immunization Practices (ACIP) recommendations. 4. Insurance: Most private plans and Medicare Part D must cover ACIP-endorsed vaccines with no cost-sharing under the Affordable Care Act. Competitive Landscape • GSK’s Arexvy and Pfizer’s Abrysvo gained U.S. approval for adults ≥60 in 2023; both companies are studying younger at-risk adults. • Moderna’s earlier start in the 18–59 segment could translate to first-mover advantage. • Combination shots: Moderna is testing an mRNA “combo booster” that targets COVID-19, flu and RSV in one jab, with Phase 3 data expected in early 2026. Public-Health Perspective Experts say widening RSV protection helps relieve hospital burden and aligns with a shift toward age- and risk-based vaccination rather than disease-specific campaigns. The move also reflects confidence in mRNA platforms for respiratory viruses beyond SARS-CoV-2. Keywords (for SEO) RSV vaccine for adults 18-59, Moderna mRESVIA FDA approval 2025, mRNA-1345 shot, RSV symptoms and prevention, new vaccines 2025, how to get the RSV vaccine, tripledemic season 2025-2026, adult immunization schedule, chronic conditions and RSV risk. Frequently Asked Questions Q: Do I still need an RSV vaccine if I’m under 60 but otherwise healthy? A: The new approval focuses on adults with medical risk factors. Healthy individuals 18–59 are not yet universally recommended but should monitor future CDC guidance. Q: Can I receive the RSV shot at the same time as my flu or COVID-19 booster? A: Yes. Current CDC guidance allows co-administration of inactivated or mRNA vaccines in different arms. Q: How long does RSV protection last? A: Data suggest antibody levels remain protective for at least one season; durability studies are ongoing. Q: Will the vaccine give me RSV? A: No. mRESVIA contains no live virus; it uses a synthetically produced mRNA fragment that cannot cause infection. Bottom Line With FDA clearance for at-risk adults under 60, Moderna’s mRESVIA broadens the RSV defense lineup just as health officials brace for another complex respiratory season. Consumers and clinicians alike now have a new tool—and a new set of decisions—on the road to comprehensive respiratory protection.